Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
about
A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continuesPathogenesis of Focal Segmental GlomerulosclerosisMoxibustion Alleviates Injury in a Rat Focal Segmental Glomerulosclerosis Model.Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations.Therapeutic targets for treating fibrotic kidney diseasesNephrotic syndrome in children: from bench to treatmentEfficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.Circulating suPAR in two cohorts of primary FSGS.Serum glomerular albumin permeability activity: association with rapid progression to end-stage renal disease in focal segmental glomerulosclerosis.Drugs and trials: lessons from Plato.Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.The glomerular permeability factors in idiopathic nephrotic syndrome.Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology.Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury.Effect of immunosuppression on the human mesangial cell cycle.Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease.Con: Biomarkers in glomerular diseases: putting the cart before the wheel?
P2860
Q26776389-FD4B19A5-03A9-45C8-B66B-7C476B7626EAQ28067299-98C5E94C-C364-4024-904F-8AF1A71F9813Q33786923-11FC9938-4CC3-4698-8F24-7E9BD9F9A8A0Q34556394-DBE71785-7A16-4DF1-B38C-F0AB275AB79EQ35079607-8C890AF9-EBB7-4CCB-BE49-6D09FDA7AA0FQ35185376-EA086110-337D-44BB-BB84-8B36AA970328Q35704498-B67A26BF-09C0-4CD7-97C4-72B65ED80D95Q36426091-A89E78D5-254B-4005-ADE4-066A7173D230Q36789030-B54C5450-1DC4-4C56-B3AE-B19D12E8AC32Q37174765-17D51BF5-C9F4-47C3-BD79-260B2F52C124Q37928188-7B10541B-A0C7-40F9-8AFB-7FC4D69BB857Q38449629-1381B5AA-7E68-4950-963B-D86EE5CA0824Q38991259-ECC1FA16-A97D-42BB-B0BB-2C3885A35D69Q41559116-48748BA7-5AE9-4CC8-B03D-C7B33D1EE622Q42563694-AE95D6BA-4362-4F29-816A-3300AD8F2E49Q50867897-5121708C-0631-4766-83C1-CF43A22F61C5Q53497916-9104A21B-15C5-4E7A-A407-0F6E4B90E114
P2860
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Novel therapies for resistant ...... I clinical trial: study design
@ast
Novel therapies for resistant ...... I clinical trial: study design
@en
type
label
Novel therapies for resistant ...... I clinical trial: study design
@ast
Novel therapies for resistant ...... I clinical trial: study design
@en
prefLabel
Novel therapies for resistant ...... I clinical trial: study design
@ast
Novel therapies for resistant ...... I clinical trial: study design
@en
P2093
P2860
P50
P356
P1433
P1476
Novel therapies for resistant ...... I clinical trial: study design
@en
P2093
Jennifer Gassman
Larysa Wickman
Melanie Joy
Michael Somers
Suzanne Vento
Tom Greene
Virginia Savin
P2860
P2888
P356
10.1186/1471-2369-12-8
P577
2011-02-10T00:00:00Z
P5875
P6179
1038031954